Anteris Technologies (AU:AVR) has released an update.
Anteris Technologies has announced promising results from their First in Human Study of the DurAVR™ THV valve, presented at New York Valves 2024, showing significant improvements in heart function for severe aortic stenosis patients. The new DurAVR™ THV transcatheter heart valve demonstrated restoration of normal blood flow and superior hemodynamic performance compared to currently available valves. These findings suggest potential long-term benefits for patients’ heart health, though further studies are needed to confirm the full effects.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
